The short answer: HBOT does not simply “boost” immunity — it modulates it. It restores oxygen-dependent bacterial killing by white blood cells, mobilizes stem cells (circulating CD34⁺ cells rose roughly 8-fold over 20 sessions in Thom et al. 2006), and can lower inflammatory cytokines like TNF-α and IL-1β. Its proven immune-relevant uses are infections and problem wounds, which are FDA-cleared. General “immune boosting” in healthy people is not.
Disclosure: Superhuman Chambers manufactures and sells hyperbaric chambers for wellness operators. This article summarizes published research and is not medical advice. HBOT is FDA-cleared only for specific indications; general immune support is not one of them. You are responsible for the protocols, claims, screening, and regulatory compliance in your jurisdiction.
”Boosting” immunity is the wrong mental model
The phrase “immune boost” is everywhere in wellness marketing, and it is almost always the wrong way to describe what a serious intervention does. A stronger, more activated immune system is not automatically a healthier one — an over-activated immune response is what drives autoimmune disease, chronic inflammation, and the cytokine storms that make some infections deadly. The goal is not a louder immune system; it is a better-regulated one.
This is exactly where HBOT gets interesting, and where honest positioning matters most. The research does not show HBOT flooring the accelerator on immunity. It shows HBOT acting as a modulator: turning up the parts of the immune response that clear infection and repair tissue, while turning down the runaway inflammatory signaling that damages it. That is a more defensible and more accurate story than “boost your immune system,” and it is the one the evidence actually supports.
Framed that way, “immune support” and “resilience” mean something specific: helping the immune system do its job in the right place at the right intensity — not maximizing it.
How HBOT modulates the immune system
Under pressure, HBOT dissolves far more oxygen into plasma than normal breathing, and that extra oxygen acts as both a fuel and a signal for immune cells. The mechanisms cut in more than one direction, which is the whole point.
| Mechanism | What the research shows | Direction |
|---|---|---|
| Oxygen-dependent bacterial killing | Neutrophils kill many bacteria via an oxygen-fueled “respiratory burst”; hypoxic infected tissue impairs it, and raising tissue oxygen restores it | Pro-defense (stimulates) |
| Direct antimicrobial effect | Oxygen is directly bacteriostatic/bactericidal to many anaerobes and shows synergy with several antibiotics | Pro-defense (stimulates) |
| Stem/progenitor mobilization | A single 2.0-ATA session doubled circulating CD34⁺ stem cells; ~8-fold rise over 20 sessions, via a nitric-oxide mechanism (Thom 2006) | Pro-repair |
| Inflammatory cytokine modulation | HBOT reduced stimulus-induced TNF-α by 29–62% and IL-1β by 23–68% in human immune cells (Benson 2003) | Anti-inflammatory (suppresses) |
| Adaptive tolerance (Treg / Th17) | In autoimmune models, HBOT expanded regulatory T cells and suppressed Th17 inflammation, partly by lowering HIF-1α | Rebalancing (tolerance) |
The two rows that look contradictory — stimulating bacterial killing while suppressing inflammatory cytokines — are the essence of modulation. In an infected, hypoxic wound, HBOT raises oxygen so leukocytes can kill bacteria. In an over-inflamed system, the same therapy damps the pro-inflammatory signaling. A 2026 narrative review spanning 39 studies described this explicitly as a context-dependent recalibration of immune set-points rather than a binary on/off effect. This connects directly to HBOT’s better-studied role in inflammation, where the same “turn it down when it’s too high” logic applies.
Where the immune benefit is actually proven: infection and wounds
The strongest immune-relevant evidence for HBOT is not in “wellness immunity” at all — it is in serious infection and impaired wound healing, and it is strong enough to be FDA-cleared and reimbursed. The mechanism is the oxygen-dependent killing above: infected, poorly perfused tissue is hypoxic, white blood cells cannot mount their oxygen-fueled attack, and HBOT restores the oxygen they need while adding a direct antimicrobial effect.
| FDA-cleared / UHMS-approved indication | Immune relevance |
|---|---|
| Clostridial myonecrosis (gas gangrene) | Oxygen is directly toxic to the anaerobic bacteria and halts toxin production |
| Necrotizing soft-tissue infections | Restores leukocyte killing in hypoxic infected tissue; antibiotic synergy |
| Refractory osteomyelitis | Improves oxygen delivery and immune function in chronically infected bone |
| Intracranial abscess | Supports host defense against anaerobic/mixed infection |
| Selected problem wounds (e.g., diabetic foot ulcers) | Restores neutrophil bactericidal capacity and drives new blood-vessel growth |
| Compromised grafts and flaps | Improves tissue oxygenation and immune-mediated healing |
These are the indications backed by the Undersea and Hyperbaric Medical Society and cleared by the FDA. If someone wants the honest “immune” headline for HBOT, this is it: in specific infections and wounds, HBOT measurably helps the immune system do its job. That is a very different — and far more supportable — claim than “boost your immunity.” Our wound-healing evidence guide covers this proven territory in depth.
Emerging: autoimmunity, post-viral resilience, and the gut
Beyond infection, a second wave of research is testing HBOT’s rebalancing effect in conditions defined by immune dysregulation — and here the story is promising but preliminary. In autoimmune and inflammatory models, HBOT has expanded regulatory T cells and suppressed Th17-driven inflammation — the same tolerance-shifting mechanism described above. In post-viral illness, the post-COVID trials reported sustained symptom and quality-of-life improvements up to a year out, consistent with — but not proof of — immune normalization. Early work in inflammatory bowel disease even points to shifts in gut-microbiome composition and reduced neutrophil over-activity.
The honest caveat is that most of this is animal models, small cohorts, or symptom-based endpoints rather than large trials with immune-normalization outcomes. The 2026 immunology review that catalogued these findings also called for standardized protocols and composite endpoints before the field can make firm clinical claims. Promising direction, early data — that is the accurate summary.
What the evidence does not support
The single most important thing to get right is what HBOT is not shown to do. There is no FDA clearance and no good evidence that HBOT “boosts immunity” in healthy people or wards off everyday colds and flu. Regulators have specifically warned about centers marketing HBOT for unapproved conditions.
- It is not a general immune booster. No trial shows HBOT makes a healthy immune system stronger or prevents routine infections.
- The effect is context-dependent and can be immunosuppressive. HBOT lowers pro-inflammatory cytokines in several settings; benefit direction depends on pressure, session count, and the condition. More is not automatically better.
- Non-infection immune data are mostly early. Treg/Th17 and microbiome findings are largely animal or small-cohort work, not large human trials.
- Post-viral evidence is small and symptom-based. Encouraging, but not an established immune-normalization claim.
- There is real safety risk. The FDA’s 2025 provider letter documents serious injuries and deaths (chiefly fire) with HBOT devices; they are cleared for specific indications only.
What this means for wellness operators
For operators, immunity is a tempting headline and a compliance trap. “Boost your immune system” is both inaccurate and the kind of claim that draws regulatory attention. The credible alternative is stronger anyway: describe HBOT as a therapy that modulates immune function, point to its genuine, FDA-cleared role in infection and wound healing, and frame everything else — autoimmune support, post-viral resilience — as active, early-stage research. If you are weighing whether to buy a hyperbaric chamber on an immunity angle, build the pitch around modulation rather than boosting from the start. That honesty is a differentiator in a category full of overreach.
Screen clients carefully, avoid any suggestion that HBOT treats or prevents infectious disease, and refer anyone with a serious infection or immune condition to a physician rather than positioning the chamber as a substitute. For the bigger picture of where HBOT is proven versus promising, our hyperbaric oxygen therapy overview and benefits page are the right anchors, and operators can talk to our team about protocols, positioning, and what claims are safe to make.
References
- Thom SR, et al. (2006). Stem cell mobilization by hyperbaric oxygen. Am J Physiol Heart Circ Physiol 290(4):H1378–86. https://journals.physiology.org/doi/full/10.1152/ajpheart.00888.2005
- Benson RM, et al. (2003). Hyperbaric oxygen inhibits stimulus-induced proinflammatory cytokine synthesis by human blood-derived monocyte-macrophages. Clin Exp Immunol 134(1):57–62. https://pmc.ncbi.nlm.nih.gov/articles/PMC1808843/
- Memar MY, et al. (2019). Hyperbaric oxygen therapy: Antimicrobial mechanisms and clinical application for infections. Biomedicine & Pharmacotherapy 109:440–447. https://doi.org/10.1016/j.biopha.2018.10.142
- Mei S, et al. (2026). Hyperbaric oxygen therapy modulates immune effector responses and reshapes peripheral immune tolerance: a narrative review. Frontiers in Immunology 17:1777972. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1777972/full
- Harnanik T, et al. (2020). Effects of Hyperbaric Oxygen on T Helper 17/Regulatory T Polarization in Antigen- and Collagen-Induced Arthritis: HIF-1α as a Target. https://pmc.ncbi.nlm.nih.gov/articles/PMC6982795/
- Hadanny A, Zilberman-Itskovich S, et al. (2024). Long-term outcomes of hyperbaric oxygen therapy in post-COVID condition: longitudinal follow-up of a randomized controlled trial. Scientific Reports 14:3604. https://www.nature.com/articles/s41598-024-53091-3
- Undersea and Hyperbaric Medical Society (15th ed.). Hyperbaric Oxygen Therapy Indications. https://uhms.org/resources/featured-resources/hbo-indications.html
- U.S. FDA (2025). Follow Instructions for Safe Use of Hyperbaric Oxygen Therapy Devices — Letter to Health Care Providers. https://www.fda.gov/medical-devices/letters-health-care-providers/follow-instructions-safe-use-hyperbaric-oxygen-therapy-devices-letter-health-care-providers
- Harvard Health Publishing. Hyperbaric oxygen therapy: Evidence-based uses and unproven claims. https://www.health.harvard.edu/healthy-aging-and-longevity/hyperbaric-oxygen-therapy-evidence-based-uses-and-unproven-claims